OptimizeRx Corp.
Company & revenue
About OptimizeRx Corp.
Financial breakdown: year ended 2025-12-31
Who they are
OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A.
Brands & revenue mix
AI-driven platform that generates dynamic audiences with predictive analytics through machine learning for life sciences brands.
Separate brand revenue is not available in this research.Source
Privacy-first process for creating consumer audiences to deliver targeted marketing campaigns.
Separate brand revenue is not available in this research.Source
Next-generation copay activation solution powered by real-time prescribing intent within the EHR workflow.
Separate brand revenue is not available in this research.Source
Tool providing insights into customers' target consumers to enhance marketing effectiveness.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Reported percentage. Percentages use consolidated company revenue unless a different denominator is stated.
Disclosed major customersPREMIUM
- AbbVie
- Merck & Co.
- Novartis
- Pfizer
Customer concentrationPREMIUM
For the rolling twelve months ended June 30, 2026, the top 20 pharmaceutical customers contributed 54% of revenue. In fiscal year 2025, the top five customers accounted for approximately 47% of revenue.
Business relationships & partnershipsPREMIUM
- DeepIntent — Integration of OptimizeRx's authenticated EHR network into DeepIntent's healthcare demand-side platform (DSP) for healthcare advertising.Source
- ConnectiveRx — A revenue-share agreement resulting from a 2014 legal settlement for financial messaging distribution through the integrated network.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
42
Weak
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
52
Fair
Financial Strength
35
Business Quality / Moat
94
Management
72
Growth Quality
10
Risk / Durability
20
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
50
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
58/100
Building Historical Record
Model Score 58/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently sees meaningful weaknesses in the company-strength profile.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
No strong positive signal is being highlighted from the currently available summary data.
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for OPRX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving OPRX's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •Is OPRX's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Does OPRX's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What future growth or profitability would be needed to justify OPRX's current valuation?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of OPRX's score?
Essential Investment Snapshot
Wall Street Score
42
Opportunity Score
50
Market Cap
$160.8M
P/E Ratio
34.3
EPS
$0.24
52-Week High
$22.25
52-Week Low
$4.54
Beta
1.09
Intrinsic Value
$9.38
Analyst Target
$11.00
Shares Outstanding
19.0M
Total Revenue
$98.7M
Total Debt
$19.5M
Dividend
No current dividend
Liquidation Value / Share
$6.90
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong upward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on OPRX.
What the Bulls Say
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Material partnership/catalyst: Integration of OptimizeRx's authenticated EHR network into DeepIntent's healthcare demand-side platform (DSP) for healthcare advertising.
- +Material partnership/catalyst: A revenue-share agreement resulting from a 2014 legal settlement for financial messaging distribution through the integrated network.
- +Product opportunity: OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.
What the Bears Say
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Healthcare Information Services industry.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
56
Jul 24, 2026
Change
-13.4
points
Current Score
42
Oct 1, 2026
Category Changes
OPRX decreased 13.4 points because Revenue declined by 6.6 points, Asset declined by 6.3 points, Capital declined by 16 points.
Negative Contributors
- − Revenue declined by 6.6 points
- − Asset declined by 6.3 points
- − Capital declined by 16 points
- − Management declined by 8 points
- − Valuation declined by 44.3 points
- − Buffett declined by 7.9 points
Projected Score
Projected Score
39
Projected Change
-2.8%
Preliminary comparable-period financial changes suggest decline of approximately 2.8 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Near Fair ValueCurrent Price
$8.57
Intrinsic Value
$9.38
Difference
−$0.81
-8.6% vs IV
Margin of Safety
8.6%
Related Companies
Medical - Healthcare Information ServicesNews
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?
OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath
OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook
Reviewing OptimizeRx (NASDAQ:OPRX) & Aclarion (NASDAQ:ACON)
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial